• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

The Weekly Roundup: August 1-5


ICYMI, this week we had stories about FDA approvals, biologics vs biosimilars, CTCL treatment, atopic dermatitis in patients with skin of color, and more.

POLL: What Conditions Do You Most Commonly Treat Patients For?

Click here to answer this week's poll.

What's New on Dermatology Times: August 1-5

Click to see a preview of what to expect this week.

Ustekinumab Approved by the FDA for Pediatric Patients with Psoriatic Arthritis

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

What are Biologics and Biosimilars, and How Are They Devolved?

Roy M. Fleischmann, MD and Joel M. Gelfand, MD, MSCE, FAAD define the terms biologic and biosimilars and discuss how they are developed.

Difference Between Biosimilars and Reference Product

Drs Roy M. Fleischmann and Joel M. Gelfand discuss differences between biosimilars and reference products.

Study Reveals Successful Results for Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces positive phase 3 results from FLASH study for the use of synthetic hypericin to reduce cutaneous T-cell lymphoma lesions.

Marketing Tips for Your Medical Practice

Harnessing digital marketing tools can help your medical practice grow.

Approaching Treatment Selection in AD

Drs Lamb, Noor, and Bhatia discuss their approach to selecting treatment in light of recent AD approvals.

Mechanism of Action and AD Treatment Selection in Patients With Skin of Color

Drs Noor and Lamb discuss mechanisms of action of biologics and JAK inhibitors and the importance of patient communication while selecting AD treatments.

Pointers with Dr Portela: 5 Treatments That Fix Eczema at the La Roche-Posay Thermal Treatment Center

In this week’s Pointers with Dr Portela, the 208SkinDoc travels to the La Roche-Posay Thermal Treatment Center.

JUVÉDERM VOLUX XC approved by FDA for jawline definition

Allergan Aesthetics announced the US Food and Drug Administration has approved the hyaluronic acid filler for jawline definition improvement.

An Interview With Shino Bay

An interview with Shino Bay Aguilera, DO, on the current state of the aesthetic industry.

Tax Increases Coming? What Physicians Need to Know About the Inflation Reduction Act

The sweeping legislation contains tax code reform, health care provisions and climate change action. What does it mean for physicians?

Related Videos
© 2024 MJH Life Sciences

All rights reserved.